NASDAQ · Diagnostics & Research · USD

Personalis, Inc. (PSNL) Stock Analysis

Personalis, Inc. (PSNL) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PSNL

$15.90

−$0.04 (−0.25%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PSNL with… →

PSNL Key Statistics

As of Oct 21, 2026

Trading

Open: $15.78
Previous Close: $15.94
Day's Range: 15.78–16.12
52-Week Range: 4.96–18.89
Volume: 2.79M
Beta: 2.32

Valuation

Market Cap: $1.70B
P/E Ratio: unprofitable
P/S ratio: 24.37
EPS (ttm): −1.09

Financials (FY)

Revenue (FY): $69.65M−17.69%
Net Income (FY): −$81.27M
Profit margin: −153.84%
Shares Outstanding: 106.80M
1-Year Return: +66.14%

Dividend and dates

Earnings Date: November 3, 2026estimated
Avg Volume: 2.91M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PSNL closed at $15.90, +66.14% over 1 year.

Personalis, Inc. (PSNL) has a market capitalization of $1.70B.

In fiscal 2025, PSNL reported revenue of $69.65M.

PSNL Stock Return by Calendar Year

Personalis, Inc. (PSNL) return since Jun 2019: what $10,000 became

1 year: $10,000 $16,614; +66.14%
5 years: $10,000 $8,175; −18.25%
Since Jun 2019: $10,000 $5,581; −44.19%

If you had invested $10,000 in Personalis, Inc. (PSNL) at the close on June 20, 2019, the earliest close on record here, it would have been worth $5,581 at the close on October 21, 2026: −44.19% in total, −7.64% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−61.74%+235.87%−61.02%−86.12%+6.06%+175.24%+37.72%+99.75%

2019*2020202120222023202420252026*

Year	Return
2026 (partial year)	+99.75%
2025	+37.72%
2024	+175.24%
2023	+6.06%
2022	−86.12%
2021	−61.02%
2020	+235.87%
2019 (partial year)	−61.74%

As of October 21, 2026.

PSNL Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$69.65M	−$81.27M	−116.7%
2024	$84.61M	−$81.28M	−96.1%
2023	$73.48M	−$108.30M	−147.4%
2022	$65.05M	−$113.32M	−174.2%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$69.65M	$15.78M	−$88.06M	−$81.27M	−116.7%
2024	$84.61M	$26.83M	−$68.27M	−$81.28M	−96.1%
2023	$73.48M	$18.21M	−$96.29M	−$108.30M	−147.4%
2022	$65.05M	$13.35M	−$115.53M	−$113.32M	−174.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PSNL Valuation vs Diagnostics & Research Median

Median of 45 stocks

Metric	PSNL	Diagnostics & Research median	vs median
P/S ratio	24.37	5.23	4.7x the median
Profit margin	−153.84%	−0.93%	152.9 pts below

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Personalis, Inc. (PSNL) at $1.70B. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 259.

The 52-week range on file runs from $4.96 to $18.89. The most recent close on file for PSNL is $15.90, dated October 21, 2026. That is −$0.04 (−0.25%) against the previous close. The latest close sits 220.89% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $69.65M. Against the prior fiscal year total of $84.61M, that is a change of −17.69%. The same year closed with a net loss of $81.27M. The reported profit margin is −153.84%. That is 152.9 percentage points below the Diagnostics & Research median of −0.93%. Earnings per share on a trailing basis come to −1.09.

Across the 4 fiscal years on file, revenue moves from $65.05M in 2022 to $69.65M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 24.37. On price-to-sales that is 4.7 times the Diagnostics & Research median of 5.23. The medians here are taken across 45 Diagnostics & Research companies that report the metric.

Over the trailing twelve months the total return is +66.14%. Across 5 years the annualized return works out at −3.95%. The reported beta is 2.32. Daily returns over the trailing 7 years annualize to a volatility of 97.05%.

Growth & Income

The record shows no dividend for PSNL.

Across the complete calendar years on file, 2020 returned +235.87% and 2022 returned −86.12%. Of the 6 complete calendar years on file, 4 finished higher. 2026 is still running; the total return is +99.75% year to date.

Peer Comparison

Personalis, Inc. (PSNL) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Personalis, Inc.	PSNL	$1.70B	—
Thermo Fisher Scientific Inc.	TMO	$256.61B	37.4
Danaher Corporation	DHR	$164.40B	41.7
Natera, Inc.	NTRA	$59.59B	—

The Diagnostics & Research industry average P/E ratio is 37.6x. Personalis, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

DHR

Danaher Corporation

$164.40B

NTRA

Natera, Inc.

$59.59B

Agilent Technologies, Inc.

$50.12B

IQV

IQVIA Holdings Inc.

$45.53B

WAT

Waters Corporation

$44.92B

View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Personalis, Inc.

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

Visit website →